Skip to content

Commit

Permalink
Built site for gh-pages
Browse files Browse the repository at this point in the history
  • Loading branch information
Quarto GHA Workflow Runner committed Aug 21, 2024
1 parent b3f9197 commit c597998
Show file tree
Hide file tree
Showing 4 changed files with 16 additions and 14 deletions.
2 changes: 1 addition & 1 deletion .nojekyll
View file
Original file line number Diff line number Diff line change
@@ -1 +1 @@
ba4caf3c
2a3e80c9
10 changes: 6 additions & 4 deletions index.html
View file
Original file line number Diff line number Diff line change
Expand Up @@ -224,9 +224,8 @@


<p>The <strong>Exeter Oncology Model: Renal Cell Carcinoma edition (EOM:RCC)</strong> is a platform cost-effectiveness model encompassing each decision node in the disease area for advanced renal cell carcinoma.</p>
<p>It has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_nodate">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_nodate" role="doc-biblioref">1</a>]</span> and the appraisal of cabozantinib plus nivolumab (TA964) <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_cabozantinib_nodate">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_cabozantinib_nodate" role="doc-biblioref"><strong>national_institute_for_health_and_care_excellence_nice_cabozantinib_nodate?</strong></a>]</span> (formerly ID6184, whilst in development).</p>
<p>The Pathways Pilot aims both at reducing the long-term resource requirements for appraisal within crowded treatment pathways and at assessing the feasibility of incorporating treatment sequences into decision making. The development of this model is described in Lee et al.&nbsp;2024. <span class="citation" data-cites="lee_nices_2024">[<a href="#ref-lee_nices_2024" role="doc-biblioref">2</a>]</span></p>
<p>This website provides …</p>
<p>It has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_renal_nodate">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_renal_nodate" role="doc-biblioref">1</a>]</span> and the appraisal of cabozantinib plus nivolumab (TA964) <span class="citation" data-cites="national_institute_for_health_and_care_excellence_nice_cabozantinib_2024">[<a href="#ref-national_institute_for_health_and_care_excellence_nice_cabozantinib_2024" role="doc-biblioref">2</a>]</span> (formerly ID6184, whilst in development). The development of this model is described in Lee et al.&nbsp;2024. <span class="citation" data-cites="lee_nices_2024">[<a href="#ref-lee_nices_2024" role="doc-biblioref">3</a>]</span></p>
<p>This website was created by <a href="https://github.com/amyheather">Amy Heather</a> <a href="https://orcid.org/0000-0002-6596-3479"><img src="../images/ORCIDiD_icon16x16.png" class="img-fluid" alt="ORCID 0000-0002-6596-347"></a>. It shares <strong>model documentation</strong> to support understanding of how the model works, and how you can use it. Please use the <strong>sidebar</strong> to navigate through the site pages.</p>



Expand All @@ -235,8 +234,11 @@
<div id="ref-national_institute_for_health_and_care_excellence_nice_renal_nodate" class="csl-entry" role="listitem">
<div class="csl-left-margin">[1] </div><div class="csl-right-inline">National Institute for Health and Care Excellence (NICE). <a href="https://www.nice.org.uk/guidance/indevelopment/gid-ta11186">Renal cell carcinoma <span>Pathways</span> <span>Pilot</span> [<span>ID6186</span>]. <span>In</span> development [<span>GID</span>-<span>TA11186</span>]</a> n.d.</div>
</div>
<div id="ref-national_institute_for_health_and_care_excellence_nice_cabozantinib_2024" class="csl-entry" role="listitem">
<div class="csl-left-margin">[2] </div><div class="csl-right-inline">National Institute for Health and Care Excellence (NICE). <a href="https://www.nice.org.uk/guidance/ta964">Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. <span>Technology</span> appraisal guidance [<span>TA964</span>]</a> 2024.</div>
</div>
<div id="ref-lee_nices_2024" class="csl-entry" role="listitem">
<div class="csl-left-margin">[2] </div><div class="csl-right-inline">Lee D, Burns D, Wilson E. <span>NICE</span>’s <span>Pathways</span> <span>Pilot</span>: <span>Pursuing</span> <span>Good</span> <span>Decision</span> <span>Making</span> in <span>Difficult</span> <span>Circumstances</span>. PharmacoEconomics - Open 2024. <a href="https://doi.org/10.1007/s41669-024-00490-x">https://doi.org/10.1007/s41669-024-00490-x</a>.</div>
<div class="csl-left-margin">[3] </div><div class="csl-right-inline">Lee D, Burns D, Wilson E. <span>NICE</span>’s <span>Pathways</span> <span>Pilot</span>: <span>Pursuing</span> <span>Good</span> <span>Decision</span> <span>Making</span> in <span>Difficult</span> <span>Circumstances</span>. PharmacoEconomics - Open 2024. <a href="https://doi.org/10.1007/s41669-024-00490-x">https://doi.org/10.1007/s41669-024-00490-x</a>.</div>
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
Expand Down
2 changes: 1 addition & 1 deletion search.json
View file
Original file line number Diff line number Diff line change
Expand Up @@ -121,7 +121,7 @@
"href": "index.html",
"title": "Exeter Oncology Model: Renal Cell Carcinoma edition",
"section": "",
"text": "The Exeter Oncology Model: Renal Cell Carcinoma edition (EOM:RCC) is a platform cost-effectiveness model encompassing each decision node in the disease area for advanced renal cell carcinoma.\nIt has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) [1] and the appraisal of cabozantinib plus nivolumab (TA964) [national_institute_for_health_and_care_excellence_nice_cabozantinib_nodate?] (formerly ID6184, whilst in development).\nThe Pathways Pilot aims both at reducing the long-term resource requirements for appraisal within crowded treatment pathways and at assessing the feasibility of incorporating treatment sequences into decision making. The development of this model is described in Lee et al. 2024. [2]\nThis website provides …\n\n\n\n\nReferences\n\n[1] National Institute for Health and Care Excellence (NICE). Renal cell carcinoma Pathways Pilot [ID6186]. In development [GID-TA11186] n.d.\n\n\n[2] Lee D, Burns D, Wilson E. NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00490-x.",
"text": "The Exeter Oncology Model: Renal Cell Carcinoma edition (EOM:RCC) is a platform cost-effectiveness model encompassing each decision node in the disease area for advanced renal cell carcinoma.\nIt has been constructed as part of the National Institute for Health and Care Excellence (NICE) Pathways Pilot appraisal (ID6186, GID-TA11186) [1] and the appraisal of cabozantinib plus nivolumab (TA964) [2] (formerly ID6184, whilst in development). The development of this model is described in Lee et al. 2024. [3]\nThis website was created by Amy Heather . It shares model documentation to support understanding of how the model works, and how you can use it. Please use the sidebar to navigate through the site pages.\n\n\n\n\nReferences\n\n[1] National Institute for Health and Care Excellence (NICE). Renal cell carcinoma Pathways Pilot [ID6186]. In development [GID-TA11186] n.d.\n\n\n[2] National Institute for Health and Care Excellence (NICE). Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. Technology appraisal guidance [TA964] 2024.\n\n\n[3] Lee D, Burns D, Wilson E. NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. PharmacoEconomics - Open 2024. https://doi.org/10.1007/s41669-024-00490-x.",
"crumbs": [
"Home"
]
Expand Down
16 changes: 8 additions & 8 deletions sitemap.xml
View file
Original file line number Diff line number Diff line change
Expand Up @@ -2,34 +2,34 @@
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/appraisals.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/publication.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/citation.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/acronyms.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/index.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/changelog.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/license.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
<url>
<loc>https://pythonhealthdatascience.github.io/stars-eom-rcc/pages/plain_english.html</loc>
<lastmod>2024-08-21T09:50:37.012Z</lastmod>
<lastmod>2024-08-21T09:58:29.619Z</lastmod>
</url>
</urlset>

0 comments on commit c597998

Please sign in to comment.